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Purpose: Previous studies have shown that progressive forms of non-alcoholic fatty liver 
disease (NAFLD) occur frequently in patients with obstructive lung disease (OLD). However, 
few studies have written about this relationship. This study aimed to investigate the relationship 
between OLD and NAFLD.
Subjects and methods: The Korea National Health and Nutrition Examination Survey is a 
national population-based, cross-sectional surveillance program that was initiated to assess the 
health and nutritional status of the Korean population. From 2007 to 2010, 11,738 subjects were 
enrolled. The subjects were defined as having NAFLD when they had scores higher than -0.640 
in a NAFLD liver fat score prediction model, which was a previously validated prediction 
score. Individuals with forced expiratory volume in one second/forced vital capacity ,0.7 
were considered to have OLD. The subjects were divided into non-OLD and OLD groups and 
non-NAFLD and NAFLD groups. All analyses were performed using sample weighting using 
the complex samples plan.
Results: The prevalences of NAFLD and OLD were 30.2% and 8.9%, respectively. Although 
not statistically significant, subjects in the NAFLD group involved a higher tendency of having 
OLD than did those in the non-NAFLD group (8.5% vs 10.0%, respectively, P=0.060). Subjects 
with OLD showed a higher tendency to have NAFLD than non-OLD subjects (30.0% vs 33.7%, 
respectively, P=0.060). NAFLD subjects were at higher odds of OLD (odds ratio=1.334; 
95% confidence interval=1.108–1.607, P=0.002) than non-NAFLD subjects, after adjusting for 
age, sex, and smoking history. OLD subjects were at higher odds of NAFLD (odds ratio=1.556; 
95% confidence interval=1.288–1.879, P,0.001) than non-OLD subjects, after adjusting for 
age, sex, and smoking history.
Conclusion: This study showed that NAFLD is related to OLD. Clinicians should be aware of 
possible liver comorbidities in OLD patients and that extrahepatic disease in NAFLD patients 
may vary more than previously thought.
Keywords: obstructive lung disease, non-alcoholic fatty liver disease, epidemiology, 
comorbidities
Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic triglyceride 
accumulation, known as steatosis, and the absence of significant alcohol consump-
tion or secondary causes (eg, viral hepatitis).1 Stemming from overnutrition and less 
physical activity, NAFLD has become the most common form of chronic liver damage. 
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Increased prevalences of obesity, diabetes, and metabolic 
syndrome have been recorded in developed and developing 
countries, drawing concern.2 NAFLD has been considered 
a hepatic manifestation of metabolic syndrome and is 
associated with various metabolic abnormalities, including 
hyperlipidemia, central obesity, type 2 diabetes, and the 
development of cardiovascular disease.3–5
Obstructive lung disease (OLD) is a category of respira-
tory disease characterized by airway obstruction.6 In patients 
with OLD, including those with COPD, metabolic syn-
drome occurs frequently.7 Emerging evidence shows that 
pulmonary function impairment is connected not only with 
cigarette smoking but also with obesity, type 2 diabetes, 
and insulin resistance, all of which are linked to increased 
oxidative stress and chronic, low-grade inﬂammation.8–10 
Additionally, prospective studies have documented that 
pulmonary function impairment is an independent pre-
dictor of cardiovascular disease-related morbidity and 
mortality.11,12
Few studies have reported the relationship between 
NAFLD and impaired lung function. Lonardo et al13 believed 
that there is strong epidemiological and clinical evidence 
supporting the notion that NAFLD and COPD, which are 
highly prevalent, non-communicable, lifestyle-related 
systemic disorders primarily clustered in the metabolic and 
cardiovascular area with a similar pathogenic background 
and a high comorbidity rate, are related not by chance but 
also by pathobiological necessity. However, this relation-
ship has not been evaluated thoroughly. We performed a 
Korean population-based study to evaluate the relationship 
between NAFLD and OLD. We aimed to evaluate whether 
1) individuals with NAFLD are at higher odds of develop-
ing OLD than non-NAFLD individuals and 2) individuals 
with OLD are at higher odds of developing NAFLD than 
non-OLD individuals.
Subjects and methods
study subjects
The Korea National Health and Nutrition Examination 
Survey (KNHANES) is a national population-based, cross-
sectional surveillance program that uses stratified random 
sampling to assess the health and nutritional status of 
Korean people.14 The Korea Centers of Disease Control 
and Prevention performed this survey to obtain statistically 
reliable and representative data; patients in nursing homes, 
soldiers, prisoners, and foreigners were excluded. A stratified, 
multistage probability sampling design, considering location 
and residence type, was used in the KNHANES to establish 
nationwide representativeness. The KNHANES database is 
publicly available at the KNHANES website (http://knhanes.
cdc.go.kr/knhanes/eng; available in English).
A ﬂow diagram of the subjects who were included in this 
study is depicted in Figure S1. Among the 33,829 subjects 
with data in the KNHANES, 2007–2010, we selected those 
aged $20 years (24,875 subjects), since pulmonary func-
tion tests were performed for subjects aged $20 years. 
Cross-sectional surveys that were conducted over a period of 
4 years were pooled for analysis. Subjects with missing 
data for pulmonary function test, liver function test, alco-
holic consumption, or hepatitis viral test were excluded 
(n=9,920). Additionally, subjects who met the following 
criteria based on our protocol were excluded: 1) alcohol 
consumption .140 g/week for men and .70 g/week for 
women (n=2,703) and 2) positivity for serologic markers 
for hepatitis B (n=490) and hepatitis C virus (n=24). Finally, 
11,738 subjects were included in the analysis and divided into 
groups according to whether OLD and NAFLD were present.
Clinical and laboratory parameters
Information regarding age, height, body weight, waist 
circumference, smoking, drinking, and additional labora-
tory results known to be related to NAFLD or OLD was 
collected for all study subjects. Age was categorized into 
three levels: ,40, 40–59, and $60 years. Responses to a 
questionnaire about smoking habits were categorized as 
never, past, or current. We excluded those with heavy alcohol 
consumption, which was defined as .140 g/week for men 
and .70 g/week for women.
After the subjects fasted overnight for .8 hours, blood 
samples were drawn from all participants during the survey, 
immediately refrigerated, and transported to the central test-
ing institute (Neodin Medical Institute, Seoul, Republic of 
Korea). All blood samples were analyzed within 24 hours 
after transportation. The serum levels of lipid and liver 
enzyme profiles were determined using a Hitachi 8,700 
automated chemistry analyzer (Hitachi, Tokyo, Japan) using 
specifically indicated methods. Spirometry data that were 
obtained by a qualified technician were assessed by another 
trained technician and the principal investigator to determine 
whether these data met the criteria for acceptability and 
reproducibility.
Hepatic steatosis and OLD definitions
NAFLD was defined using a previous validated fatty liver pre-
diction model: NAFLD liver fat score (LFS).15 Using this model, 
the risk score for NAFLD was determined as follows:
NAFLD LFS = −2.89 + 1.18 × metabolic syndrome 
(yes=1/no=0) + 0.45 × type 2 diabetes (yes=2/no=0) + 0.15 × 
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fasting sugar-insulin (mU/L) + 0.04 × (fasting sugar-aspartate 
aminotransferase/fasting sugar-alanine aminotransferase).
Metabolic syndrome was defined according to the 
criteria of the International Diabetes Federation16 (waist 
circumference, triglyceride, high-density lipoprotein choles-
terol, blood pressure, fasting glucose); type 2 diabetes was 
defined according to the criteria of the American Diabetes 
Association.17 In this prediction model, individuals with 
values greater than -0.640 were considered to have NAFLD.15 
Individuals with forced expiratory volume in 1 second/forced 
vital capacity ,0.7 were considered to have OLD.
statistical analysis
The baseline characteristics of NAFLD and non-NAFLD sub-
jects and those of OLD and non-OLD subjects were compared 
using an unpaired t-test for continuous variables or the chi-
squared test for categorical variables and are presented as a mean 
(95% confidence interval [CI]) and percentage. Continuous 
data were tested for data normality and variance homogeneity. 
To evaluate the relationship between NAFLD and OLD while 
controlling potential confounding factors, multiple logistic 
regression models were used to estimate the odds ratio [OR] for 
NAFLD and OLD. Potential confounding variables, including 
age, sex, smoking history, and NAFLD, were controlled in an 
OLD regression model. Variables, including age, sex, smoking 
history, and OLD, were controlled in the regression model of 
NAFLD. ORs and 95% CIs were calculated. Of the variables 
we collected, metabolic syndrome, diabetes, hypertension, liver 
function, and body mass index (obesity) were not included in 
the multiple logistic regression models, because they were 
included in the calculation of LFS.
As the KNHANES data are collected using a complex 
sampling design, the survey weights are provided. All analyses 
were performed using sample weighting using the complex 
samples plan, which is available as the complex samples option 
in the high version of SPSS (IBM Corporation, Armonk, NY, 
USA), to represent the total, non-institutionalized civilian 
population in Korea. All statistical analyses were performed 
using SPSS version 20.0 (IBM Corporation). An adjusted 
P-value,0.05 was considered statistically significant.
ethics statement
This study was approved annually from 2007 to 2010 by the 
institutional review board of the Korea Centers for Disease 
Control and Prevention (approval numbers: 2007-02CON-
04-P, 2008-04EXP-01-C, 2009-01CON-03-2C, and 2010-
02CON-21-C). The study was conducted in accordance with 
the ethical principles of the amended Declaration of Helsinki. 
Informed consent was obtained from each study participant.
Results
The weighted study population comprised 23,547,091 indi-
viduals. There were 16,415,120 and 7,131,971 non-NAFLD 
and NAFLD subjects, respectively. Furthermore, there were 
21,433,227 and 2,113,864 non-OLD and OLD subjects, 
respectively.
The baseline characteristics of subjects with and without 
NAFLD are shown in Table 1. NAFLD subjects were older 
than non-NAFLD subjects (45.93 vs 51.81 years, respec-
tively, P,0.001) and had a higher body mass index (23.27 
vs 26.03 kg/m2, respectively, P,0.001). The NAFLD group 
also had more ex-smokers (3.3% vs 5.9%, respectively, 
P,0.001), current smokers (31.9% vs 37.9%, respectively 
P,0.001), and a higher proportion of men (35.8% vs 48.3%, 
respectively, P,0.001) than did the non-NAFLD group. 
As hypertension, diabetes mellitus, and metabolic syndrome 
were included in the calculation of having NAFLD, subjects 
reported having these conditions more frequently than the 
non-NAFLD subjects did. NAFLD subjects showed decreased 
lung function, higher liver enzyme levels, and higher liver 
function scores than the non-NAFLD subjects. Although not 
statistically significant, subjects in the NAFLD group had a 
higher tendency to have OLD than those in the non-NAFLD 
group (8.5% vs 10.0%, respectively, P=0.060).
The baseline characteristics of subjects with and with-
out OLD are shown in Table S1. OLD subjects were older 
than non-OLD subjects (46.08 vs 64.25 years, respectively, 
P,0.001). Moreover, the OLD group had more ex- (3.3% vs 
11.8%, respectively, P,0.001) and current smokers (32.0% 
vs 51.0%, respectively, P,0.001) and a higher proportion 
of men (37.2% vs 63.3%, respectively, P,0.001) than the 
OLD group. Non-OLD subjects had a higher body mass index 
than the OLD subjects (24.18 vs 23.36 kg/m2, respectively, 
P,0.001). OLD subjects reported having hypertension, 
diabetes mellitus, and metabolic syndrome, which are related 
to NAFLD, more frequently than the non-OLD subjects did. 
OLD subjects showed decreased lung function, higher liver 
enzyme levels, and higher liver function scores than the 
non-OLD subjects. They also showed a higher tendency to 
have NAFLD than the non-OLD subjects (30.0% vs 33.7%, 
respectively, P=0.060).
Tables 2 and 3 show the relationships between OLD and 
NAFLD in the logistic regression models. When age, sex, 
smoking status, and OLD were included in the regression 
model (Table 2), OLD (OR=1.556, 95% CI=1.288–1.879, 
P,0.001) was significantly related to NAFLD. Higher age 
(40–59 years: OR=1.917, 95% CI=1.682–2.185, P,0.001, 
and $60 years: OR=3.011, 95% CI=2.509–3.613, P,0.001) 
and male sex (OR=1.852, 95% CI=1.538–2.231, P,0.001) 
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showed significant correlations with NAFLD. Unlike OLD, 
smoking status (ex-smoker: OR=0.980, 95% CI=0.808–1.189, 
P=0.694 and current smoker: OR=0.890, 95% CI=0.681–1.163, 
P=0.694) did not show a significant correlation with NAFLD.
When age, sex, smoking status, and NAFLD were included 
in the regression model (Table 3), NAFLD (OR=1.334, 
95% CI=1.108–1.607, P=0.002) was significantly related 
to OLD. Higher age (40–59 years: OR=6.196, 95% 
CI=5.102–7.525, P,0.001 and $60 years: OR=27.402, 
95% CI=17.135–43.820, P,0.001), male sex (OR=2.159, 
95% CI=1.628–2.864, P,0.001), and smoking status 
(ex-smoker: OR=2.227, 95% CI=1.569–3.300, P,0.001; 
Table 1 subject characteristics according to the presence of naFlD
Variables Non-NAFLD group NAFLD group P-value
Unweighted number, n (%) 8,168 (69.6) 3,570 (30.4)
estimated population, n (%) 16,415,120 (69.8) 7,131,971 (30.2)
age (years), % 45.93 (45.22–46.64) 51.81 (50.84–52.78) ,0.001
20–39 36.9 (34.8–39.1) 23.9 (21.4–26.6) ,0.001
40–59 42.1 (40.2–44.0) 40.7 (38.3–43.1) ,0.001
60+ 21.0 (19.6–22.5) 35.4 (33.1–37.8) ,0.001
sex (male), % 35.8 (34.2–37.4) 48.3 (45.8–50.8) ,0.001
BMI (kg/m2) 23.27 (23.17–23.38) 26.03 (25.85–26.21) ,0.001
smoking, % ,0.001
non-smoker 64.8 (63.2–66.4) 56.2 (53.7–58.6)
ex-smoker 3.3 (2.8–3.8) 5.9 (4.9–7.1)
Current smoker 31.9 (30.3–33.6) 37.9 (35.5–40.4)
smoking amount (PYrs) 18.13 (16.93–19.32) 19.28 (17.83–20.73) ,0.001
Metabolic syndrome, % 12.6 (11.4–13.8) 74.6 (72.1–77.0) ,0.001
Diabetes mellitus, % 1.8 (1.5–2.2) 24.2 (22.2–26.2) ,0.001
hypertension, % 15.5 (14.3–16.8) 50.0 (47.3–52.7) ,0.001
Pulmonary function test
FVC (l) 3.56 (3.52–3.59) 3.51 (3.45–3.56) ,0.001
FeV1 (l) 2.86 (2.83–2.89) 2.78 (2.74–2.82) ,0.001
FeV1 (%) 92.62 (92.15–93.08) 91.07 (90.44–91.70) ,0.001
FeV1/FVC ratio 0.80 (0.80–0.81) 0.79 (0.79–0.80) ,0.001
OlD, % 8.5 (7.7–9.4) 10.0 (8.8–11.4) 0.060
asT (IU/l) 19.75 (19.50–20.01) 27.22 (26.37–28.07) ,0.001
alT (IU/l) 17.40 (17.09–17.71) 33.89 (32.53–35.25) ,0.001
lFsa -1.83 (-1.86 to -1.80) 0.63 (0.55–0.71) ,0.001
Notes: Values are presented as percentage and mean (95% CI) unless otherwise specified. OLD is defined as FEV1/FVC ratio ,0.7. 
alFs = 22.89 + 1.18 × metabolic syndrome + 
0.45 × diabetes + 0.15 × fasting insulin + 0.04 × asT (IU/l) + 0.94 × asT/alT ratio.
Abbreviations: naFlD, non-alcoholic fatty liver disease; BMI, body mass index; PYrs, pack years; FVC, forced vital capacity; FeV1, forced expiratory volume; OlD, 
obstructive lung disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LFS, liver fat score; CI, confidence interval.
Table 2 logistic regression analyses of factors related to naFlD
Variables OR 95% CI P-value
age, years
20–39 1.000
40–59 1.917 1.682–2.185 ,0.001
60+ 3.011 2.509–3.613 ,0.001
sex, male 1.852 1.538–2.231 ,0.001
smoking status
never smoker 1.000
ex-smoker 0.980 0.808–1.189 0.694
Current smoker 0.890 0.681–1.163 0.694
OlD 1.556 1.288–1.879 ,0.001
Note: Values are presented as Ors with 95% CIs.
Abbreviations: naFlD, non-alcoholic fatty liver disease; Or, odds ratio; CI, 
confidence interval; OLD, obstructive lung disease.
Table 3 logistic regression analyses of factors related to OlD
Variables OR 95% CI P-value
age, years
20–39 1.000
40–59 6.196 5.102–7.525 ,0.001
60+ 27.402 17.135–43.820 ,0.001
sex, male 2.159 1.628–2.864 ,0.001
smoking status
never smoker 1.000
ex-smoker 2.227 1.569–3.300 ,0.001
Current smoker 2.016 1.517–2.680 ,0.001
naFlD 1.334 1.108–1.607 0.002
Note: Values are presented as Ors with 95% CIs.
Abbreviations: OLD, obstructive lung disease; OR, odds ratio; CI, confidence 
interval; naFlD, non-alcoholic fatty liver disease.
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current smoker: OR=2.016, 95% CI=1.517–2.680, P,0.001) 
showed significant correlations with OLD.
Discussion
The major strength of this study is that it is a large population-
based study using thoroughly collected national data, which 
enhances the statistical reliability of the results and our ability 
to generalize the data. Furthermore, to our knowledge, no 
studies have analyzed ORs of OLD in NAFLD subjects and 
ORs of NAFLD in OLD subjects in a large population-based 
study. Owing to the characteristics of the KNHANES, we 
could analyze the ORs of NAFLD and OLD subjects in both 
ways. By doing so, we could reveal a precise relationship 
between OLD and NAFLD. We demonstrated that NAFLD 
patients are at higher odds of developing OLD than did non-
NAFLD patients and that OLD patients are at higher odds of 
developing NAFLD than non-OLD patients. In light of the 
results of this study, we suggest that physicians should be 
more aware of possible liver comorbidities in OLD patients 
and that extrahepatic disease in NAFLD patients may vary 
more than previously thought. Furthermore, we believe that 
this study could provide valuable information for future 
studies. The validity of the reported confounding factors 
was also confirmed in this study population, which supports 
the consistency of the present findings. Subjects of higher 
age,18 male sex,19 and smoking history18 were at higher odds 
of OLD, while subjects of higher age and male sex20 were 
at higher odds of NAFLD.
In previous studies, the estimated prevalence of NAFLD 
was 20%–35% among the general population.21 In Korea, 
in a study of 141,610 adults who lived in an urban area 
and were 18–80 years old, the prevalence of NAFLD was 
27.3%.22 In this study, the prevalence of NAFLD was 30.2%. 
The difference in the prevalences of NAFLD may be due 
to differences in the study population (eg, age and urban-
dwelling area) and method (eg, ultrasonography and LFS). 
Additionally, in a previous study, the prevalence of OLD 
among 13,835 American adult subjects aged 19–80 years 
was 11.8%,23 and it was 13.1% in a study of 16,151 adults in 
Korea aged $40 years.24 The prevalence of OLD in this study 
was 8.9%. The difference may be due to the study population: 
we excluded subjects with hepatitis B and hepatitis C virus 
and those who consumed alcohol heavily.
Several previous studies have described a relationship 
between NAFLD and OLD. In a study of 111 subjects with 
COPD, Viglino et al25 showed that NAFLD is highly preva-
lent in individuals with COPD and might contribute to car-
diometabolic comorbidities. Similarly, Mapel and Marton26 
and Qin et al27 demonstrated that subjects who have impaired 
lung function or are diagnosed with COPD are at a higher 
risk of developing NAFLD. Other studies14,17,28,29 showed 
that NAFLD and liver disease patients have impaired lung 
function or a higher prevalence of COPD. In this context, 
the findings of this study verified and supported those of 
previous studies.
Over the last decade, it has been shown that the clinical 
burden of NAFLD is not only confined to liver-related mor-
bidity and mortality but also that NAFLD is a multisystemic 
disease that affects the extrahepatic organs and regulatory 
pathways.30 Excessive free fatty acids and chronic low-grade 
inﬂammation in visceral adipose tissue are considered to be 
two of the most important factors contributing to the pro-
gression of liver injury in NAFLD patients.31 In addition, 
secretion of adipokines from visceral adipose tissue, as well 
as lipid accumulation in the liver, further promotes inﬂam-
mation, which is activated by free fatty acids and contributes 
to insulin resistance.31 Similarly, OLD patients also tend to 
present with multiple comorbidities more frequently than 
those without OLD. The most frequent comorbidities that 
accompany OLD include cardiovascular diseases, metabolic 
disorders, osteoporosis, dysfunction of skeletal muscle, 
anxiety, depression, cognitive impairment, gastrointestinal 
diseases, and respiratory conditions, such as asthma, bron-
chiectasis, pulmonary fibrosis, and lung cancer.7 OLD is 
associated with high levels of systemic inﬂammation, prob-
ably secondary to pulmonary inﬂammation.20
Various inﬂammatory cytokines are related to NAFLD. 
Tumor necrosis factor alpha might play an initial role in 
the occurrence of steatosis, while leptin is known to have 
pro-steatotic and pro-fibrotic actions.32 An elevation in serum 
levels of interleukin-8 has been observed in patients with non-
alcoholic steatohepatitis33 and alcoholic liver disease.34 More-
over, the involvement of oxidative stress has been confirmed 
in the development of NAFLD.35 Inﬂammation and oxidative 
stress that cascades from NAFLD may play a crucial role in 
the pathogenesis of pulmonary function impairment. Mean-
while, Keatings et al36 reported that statistically significant 
increases of interleukin-8 and tumor necrosis factor-alpha 
were related to the severity of airway diseases. In a rat model, 
Liang et al37 reported that the frequency of acute exacerbation 
and severity of COPD were associated with a higher leptin 
level. Furthermore, oxidative stress is now recognized as a 
major predisposing factor in the pathogenesis of COPD.38 
As mentioned previously, these markers were also related to 
the pathogenesis of NAFLD. This could be a possible mecha-
nism for the findings in this study. However, it is uncertain 
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whether inﬂammation due to NAFLD would trigger OLD 
inﬂammation or whether inﬂammation due to OLD would 
trigger NAFLD inﬂammation. Therefore, further studies 
concerning the biochemical and metabolic mechanisms of 
these conditions are required.
This study has some limitations. First, we did not perform 
a liver biopsy, which is the gold standard for confirming a 
NAFLD diagnosis and providing prognostic information, nor 
did we perform ultrasonography, which is the most common 
diagnosis method.39 However, neither method was included 
in the KNHANES data. Instead, we used an indirect method: 
the NAFLD LFS. The NAFLD LFS shows a sensitivity of 
86% and a specificity of 71%.15 To increase the accuracy of 
identifying NAFLD, we excluded subjects with hepatitis B 
and hepatitis C viruses and those with heavy alcohol con-
sumption. We believe that using the NAFLD LFS was 
reasonable for performing an epidemiologic study to iden-
tify the relationship between NAFLD and OLD. In future 
studies, the combination of biomarkers/scores and transient 
elastography with liver ultrasonography, which were not 
performed in the current study, might confer additional 
diagnostic accuracy. Second, because a pulmonary test was 
not mandatory, some patients may have refused to take the 
pulmonary function test. In addition, patients with severe 
COPD may have had low survey participation. Therefore, 
the number of cases was possibly underestimated. Finally, 
this study only identified a relationship between OLD and 
NAFLD, but not an association between OLD and NAFLD. 
As this was a cross-sectional study, further studies are needed 
to reveal the causality between OLD and NAFLD.
Conclusion
This study showed that NAFLD is associated with OLD. 
Physicians should be aware of possible liver comorbidities 
in OLD patients and that extrahepatic disease in NAFLD 
patients may vary more than previously thought. Further 
studies concerning the biochemical and metabolic mecha-
nisms of NAFLD and OLD are required.
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Figure S1 Flow diagram of the subjects who were included in this study.
Abbreviations: PFT, pulmonary function test; asT, aspartate aminotransferase; alT, alanine aminotransferase; hBV, hepatitis B virus; hCV, hepatitis C virus; OlD, 
obstructive lung disease; naFlD, non-alcoholic fatty liver disease.
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Table S1 subject characteristics according to the presence of OlD
Variables Non-OLD group OLD group P-value
Unweighted number, n (%) 10,459 (89.1) 1,279 (10.9)
estimated population, n (%) 21,433,227 (91.1) 2,113,864 (8.9)
age (years), % 46.08 (45.47–46.70) 64.25 (63.03–65.47) ,0.001
20–39 35.7 (33.9–37.6) 5.1 (3.3–7.9) ,0.001
40–59 43.2 (41.6–44.9) 25.5 (22.2–29.1) ,0.001
60+ 21.0 (19.8–22.3) 69.4 (65.5–73.1) ,0.001
sex (male), % 37.2 (35.8–38.6) 63.3 (59.1–67.3) ,0.001
BMI (kg/m2) 24.18 (24.09–24.29) 23.36 (23.10–23.63) ,0.001
smoking, %
non-smoker 64.7 (63.3–66.0) 37.2 (33.2–41.4) ,0.001
ex-smoker 3.3 (2.9–3.8) 11.8 (9.4–14.8) ,0.001
Current smoker 32.0 (30.7–33.5) 51.0 (46.4–55.6) ,0.001
smoking history (PYrs) 16.83 (15.78–17.87) 27.80 (25.23–30.38) ,0.001
Metabolic syndrome, % 29.9 (28.4–31.3) 46.7 (42.6–50.8) ,0.001
Diabetes mellitus, % 7.9 (7.2–8.7) 15.3 (12.7–18.3) ,0.001
hypertension, % 26.2 (24.9–27.5) 47.8 (43.9–51.8) ,0.001
Pulmonary function test
FVC (l) 3.56 (3.53–3.59) 3.34 (63.03–65.47) ,0.001
FeV1 (l) 2.91 (2.88–2.93) 2.12 (2.06–2.17) ,0.001
FeV1 (%) 93.73 (93.36–94.11) 76.06 (74.88–77.23) ,0.001
FeV1/FVC ratio 0.82 (0.81–0.82) 0.63 (0.63–0.64) ,0.001
asT (IU/l) 21.94 (21.57–22.31) 22.80 (22.21–23.38) ,0.001
alT (IU/l) 22.57 (22.01–23.14) 20.60 (19.77–21.43) ,0.001
lFsa -1.10 (-1.15 to -1.05) -0.98 (-1.13 to -0.82) ,0.001
naFlD, % 30.0 (28.6–31.3) 33.7 (30–37.6) 0.060
Notes: Values are presented as percentage and mean (95% CI) unless otherwise specified. alFs = 22.89 + 1.18 × metabolic syndrome + 0.45 × diabetes + 0.15 × fasting 
insulin + 0.04 × asT (IU/l) + 0.94 × AST/ALT ratio. OLD is defined as FEV1/FVC ratio ,0.7.
Abbreviations: OlD, obstructive lung disease; BMI, Body Mass Index; PYrs, pack years; FVC, forced vital capacity; FeV1, forced expiratory volume; asT, aspartate 
aminotransferase; ALT, alanine aminotransferase; LFS, liver fat score; NAFLD, non-alcoholic fatty liver disease; CI, confidence interval.
